Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment
Ciro Celsa(Department of Health), Johann von Felden(Universität Hamburg), Brooke Wietharn(The University of Kansas Cancer Center), Tiziana Pressiani(IRCCS Humanitas Research Hospital), Amit G. Singal(Southwestern Medical Center), Celina Ang(Icahn School of Medicine at Mount Sinai), Pei‐Chang Lee(National Yang Ming Chiao Tung University), Kornelius Schulze(Universität Hamburg), Antonio D’Alessio(Hammersmith Hospital), Giuseppe Cabibbo(Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone" di Palermo), Chung‐Yen Lin(National Taiwan University), Alessandro Parisi(Marche Polytechnic University), Cristina Rigamonti(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Naoshi Nishida(Kindai University Hospital), Caterina Vivaldi(Scuola Superiore Sant'Anna), Susanna V. Ulahannan(Oklahoma State University Oklahoma City), L.A. Natola(University of Verona), Bernhard Scheiner(Medical University of Vienna), Anwaar Saeed(University of Pittsburgh), Claudia Angela Maria Fulgenzi(Università Campus Bio-Medico), Samuel Phen(The University of Texas Southwestern Medical Center), Noha Soror(University of Oklahoma Medical Center), Anjana Pillai(University of Chicago), Robert Thimme(University of Freiburg), Matthias Pinter(Medical University of Vienna), Thomas U. Marron(Icahn School of Medicine at Mount Sinai), Gianluca Masi(University of Pisa), Lorenza Rimassa(Humanitas University), Giulia Francesca Manfredi(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Salvatore Battaglia(University of Palermo), Peter R. Galle(Johannes Gutenberg University Mainz), Yi‐Hsiang Huang(First Hospital of Lanzhou University), Martin Schönlein(Universität Hamburg), Mario Pirisi(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Michela Emma Burlone(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Bernardo Stefanini(Azienda USL di Bologna), Natascha Roehlen(University of Freiburg), Arndt Vogel(Princess Margaret Cancer Centre), Anuhya Gampa(University of Chicago), David Sacerdoti(University of Verona), Roberta Ciccia(University of Palermo), Marco Enea(University of Palermo), Andrea Dalbeni(University of Verona), Wei‐Fan Hsu(China Medical University), Rohini Sharma(Hammersmith Hospital), Henning Wege(Universität Hamburg), Ryan Po-Ting Lin(Chang Gung University), Angelo Pirozzi(Humanitas University), A. Auriemma(University of Verona), Jaekyung Cheon(CHA University Bundang Medical Center)
Cited by 52
Related Papers
An inflammatory cytokine signature predicts COVID-19 severity and survival
|Nature Medicine|2020|2.7k
Simplified criteria for the diagnosis of autoimmune hepatitis†
|Hepatology|2008|1.9k
AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma
|Hepatology|2023|1.6k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2022|1.4k